|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||47.70 - 47.70|
|52 Week Range||35.49 - 52.40|
|Beta (3Y Monthly)||-0.34|
|PE Ratio (TTM)||20.47|
|Forward Dividend & Yield||1.04 (2.24%)|
|1y Target Est||N/A|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Today we will run through one way of estimating the intrinsic value of Hikma Pharmaceuticals PLC (LON...
The Grand Hack is MIT Hacking Medicine's annual flagship event dedicated to energise, infect and teach healthcare entrepreneurship and digital strategies to scale medicine as a way to solve health problems worldwide. More than 500 participants, mentors and sponsors from 25 US states and 29 countries are expected to gather on campus in the MIT Media Lab for this year's Grand Hack, the largest healthcare hackathon in the US. As a strategic sponsor, Hikma and its venture capital arm Hikma Ventures will support the Grand Hack's 'Personalised Medicine' theme, which focuses on solving challenges in improving preventative medicine, treatment affordability and personalised medicine dosages. Hikma will also have representatives on-site to speak with those attendees interested in exploring opportunities to join Hikma in its mission of putting better health within reach of millions of people through its high-quality medicines and healthcare solutions.
"Vancomycin Hydrochloride for Injection is an essential antibiotic used by hospitals to treat patients who have failed to respond to a number of other antibiotics, and it's another important addition to our growing US portfolio," said Dan Motto, Executive Vice President, Commercial and Development, Injectables.
In December 2018, Hikma Pharmaceuticals PLC (LON:HIK) announced its latest earnings update, which showed that the company turned profitable again after experiencing negative earnings in the previous financial year. Below,Read More...
NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Hikma Pharmaceuticals Plc (OTC PINK: HKMPY ) will be discussing their earnings results in their 2018 Second Half Earnings to be held on March 12, 2019, 2018 ...
(Reuters) - Hikma Pharmaceuticals Plc on Wednesday forecast growth in 2019 for its injectable drugs division, as strong demand along with a rebound in its generics business helped it post a 19 percent ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Small and large cap stocks are widelyRead More...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
Activities at upcoming ASHP conference include sponsorship of important symposium advancing patient safety practices
The Jordanian drugmaker said it sold more injectable opioids in the United States due to a supply shortage, and had a better-than-forecast performance in generics for the first half of the year as its prices proved more resilient than expected. The higher forecast in generics comes as global generic drugmakers with operations in the U.S. cut profit forecasts because of pricing pressure. Novartis said last month that 2018 sales at its generics unit, Sandoz, would fall in the low single-digit percentages, after previously holding out hopes for them to remain steady.
I am going to take a deep dive into Hikma Pharmaceuticals PLC’s (LON:HIK) most recent ownership structure, not a frequent subject of discussion among individual investors. When it comes toRead More...